Kisspeptin

Clinical Trials

Sexual Health

A neuropeptide that regulates reproductive hormone release and shows promise for treating infertility and hypogonadism.

Administration

Intravenous or subcutaneous injection

Dosage Range

1-10 nmol/kg (clinical setting)

Mechanism of Action

Kisspeptin activates GPR54 receptors on GnRH neurons, triggering the release of gonadotropin-releasing hormone which cascades to LH and FSH release, restoring natural reproductive hormone production.

Clinical Benefits

Stimulates natural testosterone/estrogen production

Supports fertility treatment

Regulates puberty onset

Potential for hypogonadism treatment

Restores HPG axis function

Clinical Evidence

Clinical trials at Imperial College London demonstrate kisspeptin's ability to stimulate reproductive hormones in both men and women. Promising results for IVF support and hypogonadotropic hypogonadism.

Side Effects

Injection site reaction

Mild abdominal discomfort

Hot flashes

Contraindications

Hormone-sensitive cancers

Pregnancy (unless supervised)

Pituitary disorders

Related Peptides in Sexual Health

PT-141 (Bremelanotide)

An FDA-approved melanocortin receptor agonist that treats hypoactive sexual desire disorder by acting directly on the central nervous system.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Peptide therapy should only be administered under the supervision of a qualified healthcare provider. Always consult your physician before starting any new treatment protocol.